Human Spasmolytic Polypeptide in Glycosylated Form
    2.
    发明申请
    Human Spasmolytic Polypeptide in Glycosylated Form 审中-公开
    人解脂多糖在糖基化形式

    公开(公告)号:US20090011461A1

    公开(公告)日:2009-01-08

    申请号:US12040141

    申请日:2008-02-29

    IPC分类号: C12P21/04

    CPC分类号: C07K14/575 A61K38/00

    摘要: Human spasmolytic polypeptide (HSP) which has the amino acid sequence Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyror a functionally equivalent homologue thereof, characterized by being in glycosylated form.

    摘要翻译: 具有氨基酸序列的人解痉多肽(HSP)Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr或其功能等同同系物,其特征在于呈糖基化形式。

    Human spasmolytic polypeptide in glycosylated form
    4.
    发明申请
    Human spasmolytic polypeptide in glycosylated form 审中-公开
    人解痉多肽以糖基化形式存在

    公开(公告)号:US20050287640A1

    公开(公告)日:2005-12-29

    申请号:US11139749

    申请日:2005-05-27

    CPC分类号: C07K14/575 A61K38/00

    摘要: Human spasmolytic polypeptide (HSP) which has the amino acid sequence Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro His Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile Thr Ser Asp Gln Cys Phe Asp Asn Gly Cys Cys Phe Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Ser Asn Phe Ile Phe Glu Val Pro Trp Cys Phe Phe Pro Asn Ser Val Glu Asp Cys His Tyr or a functionally equivalent homologue thereof, characterized by being in glycosylated form.

    摘要翻译: 具有氨基酸序列

    Glu Lys Pro Ser Pro Cys Gln Cys Ser Arg Leu Ser Pro他的Asn Arg Thr Asn Cys Gly Phe Pro Gly Ile ROW> <进入> Asp Ser Ser Val Thr Gly Val Pro Trp Cys Phe His < 进入> Pro Leu Pro Lys Gln Glu Ser Asp Gln Cys Val Met Glu Val Ser Asp Arg Arg Asn Cys Gly Tyr Pro Gly Ile Ser Pro Glu Glu Cys Ala Ser Arg Lys Cys Cys Phe Pro Asn Ser Val Glu Asp Cys His Tyr 或其功能等同同系物,其特征在于呈糖基化形式。

      Human Kunitz-type protease inhibitor variants
      7.
      发明授权
      Human Kunitz-type protease inhibitor variants 失效
      人类Kunitz型蛋白酶抑制剂变体

      公开(公告)号:US5629176A

      公开(公告)日:1997-05-13

      申请号:US334773

      申请日:1994-11-04

      CPC分类号: C07K14/8114 A61K38/00

      摘要: A variant of the C-terminal Kunitz-type protease inhibitor domain of the .alpha.3 chain of human type VI collagen, the variant comprising the following amino acid sequence X.sup.1 X.sup.16 Asp Ile Cys Lys Leu Pro Lys Asp X.sup.2 Gly X.sup.3 Cys X.sup.4 X.sup.5 X.sup.6 X.sup.7 X.sup.8 X.sup.9 Trp Tyr Tyr Asp Pro Asn Thr Lys Ser Cys Ala Arg Phe X.sup.10 Tyr Gly Gly Cys X.sup.11 X.sup.12 X.sup.13 Glu Asn Lys Phe X.sup.14 Ser Gln Lys Glu Cys Glu Lys Val Cys Ala Pro X.sup.15 (SEQ ID NO. 1) wherein X.sup.1, X.sup.15, and X.sup.16 represents a naturally occurring amino acid residues except Cys and X.sup.2 -X.sup.14 each independently respresents a naturally occurring amino acid residue, with the proviso that at least one of the amino acid residues X.sup.1 -X.sup.16 is different from the corresponding amino acid residue of the native sequence. Alternatively, the N-terminal Asp may be preceded by H or 3-5 amino acid residues and the C-terminal Pro may be followed by OH or 3-5 amino acid residues.

      摘要翻译: 人类VI型胶原α3链的C末端Kunitz型蛋白酶抑制剂结构域的变体,该变体包含以下氨基酸序列X1 X16 Asp Ile Cys Lys Leu Pro Lys Asp X2 Gly X3 Cys X4 X5 X6 X7 X8 X9 Trp Tyr Tyr Asp Pro Asn Thr Lys Ser Cys Ala Arg Phe X10 Tyr Gly Gly Cys X11 X12 X13 Glu Asn Lys Phe X14 Ser Gln Lys Glu Cys Glu Lys Val Cys Ala Pro X15(SEQ ID NO.1)其中X1, X15和X16表示天然存在的氨基酸残基,除了Cys和X2-X14各自独立地表示天然存在的氨基酸残基,条件是至少一个氨基酸残基X1-X16不同于相应的氨基酸残基 的天然序列。 或者,N-末端Asp可以在H或3-5​​个氨基酸残基之前,C末端Pro可以之后是OH或3-5​​个氨基酸残基。

      Yeast processing system
      9.
      发明授权
      Yeast processing system 失效
      酵母加工系统

      公开(公告)号:US5395922A

      公开(公告)日:1995-03-07

      申请号:US196887

      申请日:1994-02-15

      摘要: A polypeptide for production in yeast comprises a fusion of a signal peptide, a leader peptide and a heterologous protein or polypeptide. The polypeptide is modified in its amino acid sequence adjacent to a yeast processing site positioned between the C-terminal end of the leader peptide and the N-terminal end of the heterologous protein so as to provide a presentation of the processing site which makes it accessible to proteolytic cleavage. Such a presentation is provided by adding one or more amino acids (at least one of which is negatively charged) to either the C-terminal end of the leader or the N-terminal end of the protein, or both. The heterologous protein may, for instance, be aprotinin or insulin precursor or an analogue thereof.

      摘要翻译: 用于在酵母中生产的多肽包括信号肽,前导肽和异源蛋白质或多肽的融合物。 该多肽在与位于前导肽的C-末端和异源蛋白质的N-末端之间的酵母加工位点相邻的氨基酸序列中被修饰,从而提供使得其可接近的处理位点的呈现 蛋白水解切割。 通过将一个或多个氨基酸(其中至少一个带负电荷)添加到前导序列的C-末端或蛋白质的N-末端或二者之间来提供这种呈递。 异源蛋白质可以是例如抑肽酶或胰岛素前体或其类似物。